Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Feldkirch, Graz, Linz, Mattersburg, St. Stefan ob Stainz, Vienna, and Wien, AustriaSee the 8 sites
- Phase
- Phase 3
Where in Austria
- VIVITFeldkirch, AustriaTaking people
- Medizinische Universität GrazGraz, AustriaTaking people
- Ordensklinikum Linz GmbHLinz, AustriaTaking people
- Cardio Metabolic CentreMattersburg, AustriaTaking people
- Ordination Dr. Evelyn Fliesser-GörzerSt. Stefan ob Stainz, AustriaTaking people
- Dr. Distelmaier & Dr. Goliasch Gruppenpraxis Fuer Innere Medizin Und Kardiologie OGVienna, AustriaTaking people
- Klinik HietzingVienna, AustriaTaking people
- Klinik FloridsdorfWien, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.